inclisiran
NICE backs NHS use of Novartis’ cholesterol drug Leqvio
Phil Taylor
cholesterol, gene silencing, HEOR, inclisiran, Leqvio, market access, NHS, NICE, Novartis, RNAi
0 Comment
Novartis tries to rescue stalled inclisiran filing with FDA
Phil Taylor
Alnylam, cardiology, cholesterol, fda, inclisiran, Novartis
0 Comment
FDA rejects Novartis’ cholesterol drug after factory inspection issue
Richard Staines
Alnylam, cardiology, fda, inclisiran, Novartis
0 Comment
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drug
Phil Taylor
cardiovascular disease, CHMP, cholesterol, ema, inclisiran, Leqvio, Novartis
0 Comment
Novartis plots cardio trial in UK as London HQ opens
Richard Staines
cardiovascular, clinical trials, inclisiran, market access, NHS, NICE, Novartis, R&D
0 Comment
Market Access/ News/ News/ News/ Patients/ Top stories
Novartis strikes landmark deal with NHS to speed up inclisiran access
Phil Taylor
cardiovascular disease, cholesterol, inclisiran, NHS England, Novartis
0 Comment
TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?
Phil Taylor
Amgen, cardiovascular disease, cholesterol, gene silencing, inclisiran, PCSK9 inhibitors, Praluent, Regeneron, Repatha, RNA interference, Sanofi, The Medicines Company
0 Comment
TMC inches closer to inclisiran approval with long-term safety data
Phil Taylor
cholesterol, inclisiran, The Medicines Company, TMC
0 Comment